Rheumatoid arthritis

American Journal of Nursing

Volumn 100, Issue 11, 2000, Pages 40-43

  Ramsburg, Karen L ^a  

^a Arthritis and Osteoporosis Center of Maryland   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; BIOLOGICAL RESPONSE MODIFIER; IMMUNOGLOBULIN G; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; HUMAN; IMMUNOLOGY; PATHOPHYSIOLOGY; REVIEW; RHEUMATOID ARTHRITIS;

ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL RESPONSE MODIFIERS; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; STEROIDS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034322060     PISSN: 0002936X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000446-200011000-00042     Document Type: Article

References (21)

1. Feldmann M, et al. Rheumatoid arthritis. Cell 1996;85(3):307-10.
2. Callahan LF. The burden of rheumatoid arthritis: facts and figures. J Rheumatol Suppl 1998;53:8-12.
3. Singh G, et al. Direct costs of medical care in rheumatoid arthritis: patterns and role of rheumatology care. Direct costs of medical care in rheumatoid arthritis: patterns and role of rheumatology care. Arthritis Rheum 1997;40(Suppl):S170.
4. Slotkoff AT, Katz P. Approach to the patient with rheumatoid arthritis. Adv Intern Med 1994;39:197-240.
5. Anderson ST. Mortality in rheumatoid arthritis: do age and gender make a difference? Semin Arthritis Rheum 1996;25(5):291-6.
6. Arnett FC, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31(3):315-24.
7. The Communications and Marketing Committee of the American College of Rheumatology. Update on new agents for arthritis: celebrex (celecoxib): patient information. ACR Hotline 1999 Mar 30. http://www.rheumatology.org/ research/hotline/3drugs.html.
8. Spiera RF. Patient information: rofecoxib (vioxx). ACR Hotline 1999 Jul 13. http://www.rheumatology.org/patients/ hotline/vioxxfinal71399.html.
9. Egsmose C, et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year follow-up of a prospective double blind placebo controlled study. J Rheumatol 1995;22(12):2208-13.
10. Gardner G, Furst DE. Disease-modifying antirheumatic drugs. Potential effects in older patients. Drugs Aging 1995;7(6):420-37.
11. Salach RH, Cash JM. Methotrexate: the emerging drug of choice for serious rheumatoid arthritis. Clin Ther 1994;16(6):912-22.
12. Choy E, Kingsley G. How do second-line agents work? Br Med Bull 1995;51(2):472-92.
13. Weinblatt ME, et al. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum 1994;37(10):1492-8.
14. Arthritis Foundation. Disease-modifying antirheumatic drugs [online]. 2000. http://www.arthritis.org/answers/drugguide/ dmards.asp.
15. Cherwinski HM, et al. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism. J Pharmacol Exp Ther 1995;272(1):460-8.
16. Arthritis Foundation. Juvenile rheumatoid arthritis (JRA) [online]. 2000. http://www.arthritis.org/answers/ diseasecenter/jra.asp.
17. Moreland LW, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337(3):141-7.
18. Moreland LW, et al. Long-term safety and efficacy of TNF receptor (p75) Fc fusion protein (TNFR:Fc;Enbrel™) in DMARD refractory rheumatoid arthritis (RA). Arthritis Rheum 1998;41(9 Suppl):S364.
19. Moreland LW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130(6):478-86.
20. Weinblatt ME, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340(4):253-9.
21. Furst DE, et al. Recapitulation of the round-table discussion - assessing the role of anti-tumour necrosis factor therapy in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 1999;38(Suppl 2):50-3.